Latest

Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.–Irish Trade Implications ◆ AI in Pharma H1 2026 Report: Mega-Deals, On-Premise Supercomputer Factories, and Clinical Translation Milestones ◆ Using LLMs Safely in Pharma: The Employee Guide to Risk Mitigation, Ethics, and GxP Compliance ◆ US Pharmaceutical Tariffs Update: Policy Realities, The Stockpile 'Unwind', and Ireland’s Strategic Position ◆ US Biopharma Group Pfanstiehl Acquires Nestlé’s Former Askeaton Infant Formula Site in Landmark Mid-West Industrial Transition ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.–Irish Trade Implications ◆ AI in Pharma H1 2026 Report: Mega-Deals, On-Premise Supercomputer Factories, and Clinical Translation Milestones ◆ Using LLMs Safely in Pharma: The Employee Guide to Risk Mitigation, Ethics, and GxP Compliance ◆ US Pharmaceutical Tariffs Update: Policy Realities, The Stockpile 'Unwind', and Ireland’s Strategic Position ◆ US Biopharma Group Pfanstiehl Acquires Nestlé’s Former Askeaton Infant Formula Site in Landmark Mid-West Industrial Transition ◆

Search Results

Found 1 result for "norway" across articles, medicines, trials, companies and the glossary

The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector

The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector

An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.